Quest Diagnostics saw the highest growth of 0.99% in patent filings in June and 1.79% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.74% and grants by 1.79%. GlobalData’s DataBook provides a comprehensive analysis of Quest Diagnostics‘s patent filings and grants. Buy the databook here.
Quest Diagnostics has been focused on protecting inventions in United States(US) with 15 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 58% filings and 44% grants. The United States(US), Japan(JP), European Patent Office(EPO), and Canada(CA) patent Office are among the top ten patent offices where Quest Diagnostics is filings its patents. Among the top granted patent authorities, Quest Diagnostics has 44% of its grants in United States(US), 17% in European Patent Office(EPO) and 17% in Canada(CA).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for Quest Diagnostics
Patents related to industrial automation and cell & gene therapy lead Quest Diagnostics's portfolio
Quest Diagnostics has the highest number of patents in industrial automation followed by, cell & gene therapy and rare diseases. For industrial automation, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Adenomas related patents lead Quest Diagnostics portfolio followed by craniopharyngioma, and meningioma
Quest Diagnostics has highest number of patents in adenomas followed by craniopharyngioma, meningioma, voice recognition, and bladder carcinoma.
For comprehensive analysis of Quest Diagnostics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.